WO2000007583A3 - Treatment of addiction and addiction-related behavior - Google Patents

Treatment of addiction and addiction-related behavior Download PDF

Info

Publication number
WO2000007583A3
WO2000007583A3 PCT/US1999/017220 US9917220W WO0007583A3 WO 2000007583 A3 WO2000007583 A3 WO 2000007583A3 US 9917220 W US9917220 W US 9917220W WO 0007583 A3 WO0007583 A3 WO 0007583A3
Authority
WO
WIPO (PCT)
Prior art keywords
addiction
gaba
pharmaceutically acceptable
effective amount
gamma
Prior art date
Application number
PCT/US1999/017220
Other languages
French (fr)
Other versions
WO2000007583A2 (en
Inventor
Stephen L Dewey
Jonathan D Brodie
Charles R Ashby Jr
Original Assignee
Brookhaven Science Ass Llc
Stephen L Dewey
Jonathan D Brodie
Charles R Ashby Jr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/129,253 external-priority patent/US6057368A/en
Priority to DE69931789T priority Critical patent/DE69931789T2/en
Priority to HU0103377A priority patent/HUP0103377A3/en
Priority to NZ509682A priority patent/NZ509682A/en
Priority to BR9912760-1A priority patent/BR9912760A/en
Priority to PL347912A priority patent/PL198789B1/en
Priority to EP99941982A priority patent/EP1102583B1/en
Priority to KR1020017001525A priority patent/KR20010085332A/en
Application filed by Brookhaven Science Ass Llc, Stephen L Dewey, Jonathan D Brodie, Charles R Ashby Jr filed Critical Brookhaven Science Ass Llc
Priority to JP2000563268A priority patent/JP2002522383A/en
Priority to IL14106799A priority patent/IL141067A0/en
Priority to MXPA01001268A priority patent/MXPA01001268A/en
Priority to CA002339192A priority patent/CA2339192C/en
Priority to AU55452/99A priority patent/AU772715B2/en
Publication of WO2000007583A2 publication Critical patent/WO2000007583A2/en
Publication of WO2000007583A3 publication Critical patent/WO2000007583A3/en
Priority to NO20010539A priority patent/NO20010539L/en
Priority to HR20010085A priority patent/HRP20010085A2/en
Priority to CY20061101262T priority patent/CY1105214T1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse

Abstract

The present invention provides a method for changing addiction-related behavior of a mammal suffering from addiction to abused drugs, such as cocaine, nicotine, methamphetamine, ethanol, morphine, heroin and combinations thereof. The method includes administering to the mammal an effective amount of a compound increasing central nervous system GABA levels, wherein the effective amount is sufficient to diminish, inhibit or eliminate behavior associated with craving or use of abused drugs. Said compound may be gamma vinyl GABA (GVG), a pharmaceutically acceptable salt thereof, or an enantiomer or a racemic mixture thereof, or may be gabapentin, valproic acid, progabide, gamma-hydroxybutyric acid, fengabine, cetyl GABA, topiramate, tiagabine, acamprosate, pharmaceutically acceptable saltsthereof, enantiomers or racemic mixtures thereof.
PCT/US1999/017220 1998-08-05 1999-08-05 Treatment of addiction and addiction-related behavior WO2000007583A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
JP2000563268A JP2002522383A (en) 1998-08-05 1999-08-05 Treatment of addiction or addiction-related behavior
IL14106799A IL141067A0 (en) 1998-08-05 1999-08-05 Treatment of addiction and addiction-related behavior
HU0103377A HUP0103377A3 (en) 1998-08-05 1999-08-05 Treatment of addiction and addiction-related behavior
MXPA01001268A MXPA01001268A (en) 1998-08-05 1999-08-05 Treatment of addiction and addiction-related behavior.
PL347912A PL198789B1 (en) 1998-08-05 1999-08-05 Treatment of addiction and addiction-related behavior
EP99941982A EP1102583B1 (en) 1998-08-05 1999-08-05 Treatment of addiction to nicotine and addiction-related behavior
KR1020017001525A KR20010085332A (en) 1998-08-05 1999-08-05 Treatment of addiction and addition-related behavior
DE69931789T DE69931789T2 (en) 1998-08-05 1999-08-05 TREATMENT OF NICOTINE ASK AND SEEK CONDITIONAL BEHAVIOR
AU55452/99A AU772715B2 (en) 1998-08-05 1999-08-05 Treatment of addiction and addiction-related behavior
NZ509682A NZ509682A (en) 1998-08-05 1999-08-05 Method of treating addictive behaviour by administering a GVG drug also known as the epileptic vigabatrin (sabril)
BR9912760-1A BR9912760A (en) 1998-08-05 1999-08-05 Uses of vinylgaba gamma (gvg) and a composition that increases gaba levels in the central nervous system
CA002339192A CA2339192C (en) 1998-08-05 1999-08-05 Treatment of addiction and addiction-related behavior
NO20010539A NO20010539L (en) 1998-08-05 2001-01-31 Treatment of addiction and addiction-related behavior
HR20010085A HRP20010085A2 (en) 1998-08-05 2001-02-02 Treatment of addiction and addiction-related behavior
CY20061101262T CY1105214T1 (en) 1998-08-05 2006-09-05 TREATMENT OF NICOTINE ADDICTION AND RELATED ADDICTIVE BEHAVIOR

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US09/129,253 1998-08-05
US09/129,253 US6057368A (en) 1998-08-05 1998-08-05 Treatment of addiction and addiction-related behavior
US09/189,166 1998-11-09
US09/189,166 US6828349B1 (en) 1998-08-05 1998-11-09 Treatment of addiction and addiction-related behavior
US09/209,952 1998-12-11
US09/209,952 US6541520B1 (en) 1998-08-05 1998-12-11 Treatment of addiction and addiction-related behavior

Publications (2)

Publication Number Publication Date
WO2000007583A2 WO2000007583A2 (en) 2000-02-17
WO2000007583A3 true WO2000007583A3 (en) 2000-09-08

Family

ID=27383860

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/017220 WO2000007583A2 (en) 1998-08-05 1999-08-05 Treatment of addiction and addiction-related behavior

Country Status (24)

Country Link
US (4) US6541520B1 (en)
EP (1) EP1102583B1 (en)
JP (1) JP2002522383A (en)
CN (1) CN1172663C (en)
AT (1) ATE328588T1 (en)
AU (1) AU772715B2 (en)
BR (1) BR9912760A (en)
CA (1) CA2339192C (en)
CY (1) CY1105214T1 (en)
CZ (1) CZ2001394A3 (en)
DE (1) DE69931789T2 (en)
DK (1) DK1102583T3 (en)
ES (1) ES2267287T3 (en)
HR (1) HRP20010085A2 (en)
HU (1) HUP0103377A3 (en)
ID (1) ID28916A (en)
IL (1) IL141067A0 (en)
MX (1) MXPA01001268A (en)
NO (1) NO20010539L (en)
NZ (1) NZ509682A (en)
PL (1) PL198789B1 (en)
PT (1) PT1102583E (en)
TW (1) TWI243674B (en)
WO (1) WO2000007583A2 (en)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6890951B2 (en) * 1998-08-05 2005-05-10 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior
CA2341400A1 (en) * 1998-08-25 2000-03-02 Sepracor, Inc. Methods and compositions employing optically pure s(+) vigabatrin
JP2002527470A (en) * 1998-10-20 2002-08-27 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Anticonvulsant derivatives useful in the treatment of alcoholism, addiction and abuse
MXPA01008537A (en) * 1999-02-24 2005-02-17 Univ Cincinnati Use of sulfamate derivatives for treating impulse control disorders.
WO2000066108A2 (en) * 1999-04-30 2000-11-09 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating cocaine dependency
IT1313585B1 (en) * 1999-07-30 2002-09-09 Neuroscienze S C A R L USE OF GABAB RECEPTOR AGONISTS FOR THE MAINTENANCE THERAPY OF NICOTINE ABSTINENCE IN NICOTINO-EMPLOYEES.
US6395783B1 (en) * 2000-10-23 2002-05-28 Brookhaven Science Associates, Llc Treatment of PCP addiction and PCP addiction-related behavior
US20050192271A1 (en) * 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
US20020187996A1 (en) * 2001-05-14 2002-12-12 Dewey Stephen L. Prevention of addiction in pain management
US6462084B1 (en) * 2001-05-14 2002-10-08 Brookhaven Science Associates, Llc Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
UA78211C2 (en) 2001-07-09 2007-03-15 Ortho Mcneil Pharm Inc Salts of fructopyranose derivatives as anticonvulsant
US7041650B2 (en) 2001-07-09 2006-05-09 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivative salts
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US7822470B2 (en) * 2001-10-11 2010-10-26 Osypka Medical Gmbh Method for determining the left-ventricular ejection time TLVE of a heart of a subject
US20090088443A1 (en) * 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US6559293B1 (en) 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
AU2003213719A1 (en) 2002-03-01 2003-09-16 Regents Of The University Of Michigan Multiple-component solid phases containing at least one active pharmaceutical ingredient
US6797707B2 (en) * 2002-03-29 2004-09-28 University Of Florida Antagonists of RF-amide neuropeptides
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
CN100360117C (en) 2002-06-21 2008-01-09 转化医药公司 Pharmaceutical compositions with improved dissolution
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
EP3326617A1 (en) 2004-06-12 2018-05-30 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
US20070231268A1 (en) * 2004-11-24 2007-10-04 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060110327A1 (en) * 2004-11-24 2006-05-25 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060177380A1 (en) * 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
AR055792A1 (en) * 2005-05-17 2007-09-05 Wm Internat Ltd APPARATUS AND METHOD FOR THE NON-CHEMICAL STABILIZATION OF BIO-SOLIDS
CN101754947A (en) 2005-05-20 2010-06-23 詹森药业有限公司 The preparation method of sulfone amide derivative
EP1937236A2 (en) * 2005-09-07 2008-07-02 Braincells, Inc. Modulation of neurogenesis by hdac inhibition
US20070134169A1 (en) * 2005-12-11 2007-06-14 Rabinoff Michael D Methods for smoking cessation or alcohol cessation or other addiction cessation
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
AR058389A1 (en) 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv USE OF SULFAMIDE BENZO-FUSED HETEROCICLIC DERIVATIVES FOR THE TREATMENT OF OBESITY
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
DE102006016990A1 (en) * 2006-04-11 2007-10-18 Hermann, Holger Lars, Dr. Use of baclofen compounds to treat dependence on gamma-hydroxybutyrate or its analogs
AU2007253814A1 (en) 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy
US20080103111A1 (en) * 2006-06-21 2008-05-01 Harlan Clayton Bieley Smoking Cessation Treatment with Appetite Suppression
US20100021570A1 (en) * 2006-06-21 2010-01-28 Harlan Clayton Bieley Smoking Cessation Treatment By Reducing Nicotine Cravings, Apetite Suppression, And Altering The Perceived Taste Of Tobacco Smoke
US20090239942A1 (en) * 2006-09-15 2009-09-24 Cloyd James C Topiramate Compositions and Methods of Making and Using the Same
US20080194519A1 (en) * 2006-09-15 2008-08-14 Regents Of The University Of Minnesota Topiramate compositions and methods for their use
US20090270438A1 (en) * 2006-10-18 2009-10-29 Clive Booles Novel compositions and formulations
JPWO2008090736A1 (en) * 2007-01-23 2010-05-20 公立大学法人名古屋市立大学 Medicament for the prevention and treatment of Alzheimer type dementia
EP2182804B1 (en) * 2007-08-06 2017-05-24 Biotie Therapies, Inc. Methods for treating dependence
WO2009051824A2 (en) * 2007-10-18 2009-04-23 Aiko Biotechnology Combination analgesic employing opioid and neutral antagonist
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
AU2009271362B2 (en) 2008-06-23 2014-03-13 Janssen Pharmaceutica Nv Crystalline form of (2s)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
WO2011041451A2 (en) * 2009-09-30 2011-04-07 Harlan Clayton Bieley Smoking cessation with body weight maintenance and nutritional supplement
EP3064064A1 (en) * 2009-09-30 2016-09-07 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
CA2790820A1 (en) * 2010-02-25 2011-09-01 Northwestern University Use (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid as a gaba aminotransferse inhibitor
US20120046232A1 (en) * 2010-06-22 2012-02-23 Medical University Of South Carolina Compositions and methods for reducing relapse of addictive behavior
CN104873455B (en) 2010-12-22 2023-09-12 普渡制药公司 Coated Tamper Resistant Controlled Release Dosage Forms
US9233073B2 (en) 2010-12-23 2016-01-12 Purdue Pharma L.P. Tamper resistant solid oral dosage forms
US20140072936A1 (en) * 2012-09-07 2014-03-13 Patrick D. Herron Method of Tracking Consumption and Associated Effects
MX366159B (en) 2012-11-30 2019-07-01 Acura Pharmaceuticals Inc Self-regulated release of active pharmaceutical ingredient.
EA201500742A1 (en) 2013-02-05 2015-12-30 Пердью Фарма Л.П. PHARMACEUTICAL COMPOSITIONS PROTECTED FROM NON-GOAL USE
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
WO2015145459A1 (en) 2014-03-26 2015-10-01 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release coated reservoir solid dosage form
WO2015187289A1 (en) 2014-06-03 2015-12-10 Pop Test Abuse Deterrent Technology Llc Drug device configured for wireless communication
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
WO2017222575A1 (en) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Process of making more stable abuse-deterrent oral formulations
CN114903006A (en) * 2021-02-09 2022-08-16 中国科学院脑科学与智能技术卓越创新中心 Construction method and application of non-human primate substance addiction model
EP4334282A1 (en) * 2021-05-05 2024-03-13 Mind Medicine, Inc. Mdma enantiomers
CN115386421A (en) * 2022-06-23 2022-11-25 江苏华熙益能生物科技有限公司 Tobacco essence, preparation method and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0024965A1 (en) * 1979-07-26 1981-03-11 Merrell Toraude Et Compagnie Fluorinated methyl beta-alanine derivatives, their preparation and pharmaceutical compositions containing them
WO1989003211A1 (en) * 1987-10-07 1989-04-20 Matrix Technologies, Incorporated Treatment of cocaine addiction
EP0509180A1 (en) * 1991-04-18 1992-10-21 Merrell Dow Pharmaceuticals Inc. Use of GABA-T inhibitors for the treatment of schizophrenia and phencyclidine intoxication

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3639607A (en) 1970-11-02 1972-02-01 Jack E Phillips Method for treating the tobacco smoking habit
US3960927A (en) 1975-03-18 1976-06-01 Richardson-Merrell Inc. Olefinic derivatives of amino acids
GB2133002B (en) 1982-12-30 1986-01-29 Merrell Toraude & Co Process for preparing 4-amino-5-hexenoic acid
GB8311804D0 (en) 1983-04-29 1983-06-02 Merrell Toraude & Co Treatment of seizure disorders and pharmaceutical compositions
US4595697A (en) 1984-03-28 1986-06-17 Merrell Dow Pharmaceuticals Inc. Treatment of seizure disorders and pharmaceutical compositions useful therein
US5189064A (en) * 1985-07-22 1993-02-23 Matrix Technologies, Inc. Treatment of cocaine addiction
US5189026A (en) * 1991-06-07 1993-02-23 Fractal Laboratories, Inc. Treatment of human diseases involving dysregulation or dysfunction of the nervous system
GB9125615D0 (en) * 1991-12-02 1992-01-29 Wyeth John & Brother Ltd Amines
US5332736A (en) * 1993-11-01 1994-07-26 Ortho Pharmaceutical Corporation Anti-convulsant aroyl aminoacylpyrroles
US5824684A (en) * 1997-02-21 1998-10-20 Synapse Pharmaceuticals International, Inc. Method for treating drug and alcohol addiction
US5760049A (en) * 1997-02-21 1998-06-02 Synapse Pharmaceuticals International, Inc. Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use
CO4970824A1 (en) 1997-10-28 2000-11-07 Schering Corp METHOD TO REDUCE ANXIES OF CONSUMPTION IN MAMMALS
JP2002527470A (en) 1998-10-20 2002-08-27 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Anticonvulsant derivatives useful in the treatment of alcoholism, addiction and abuse
MXPA01008537A (en) 1999-02-24 2005-02-17 Univ Cincinnati Use of sulfamate derivatives for treating impulse control disorders.
WO2000066108A2 (en) 1999-04-30 2000-11-09 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating cocaine dependency

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0024965A1 (en) * 1979-07-26 1981-03-11 Merrell Toraude Et Compagnie Fluorinated methyl beta-alanine derivatives, their preparation and pharmaceutical compositions containing them
WO1989003211A1 (en) * 1987-10-07 1989-04-20 Matrix Technologies, Incorporated Treatment of cocaine addiction
EP0509180A1 (en) * 1991-04-18 1992-10-21 Merrell Dow Pharmaceuticals Inc. Use of GABA-T inhibitors for the treatment of schizophrenia and phencyclidine intoxication

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
DEWEY ET AL.: "A new GABAergic stategyfor treating cocaine addiction", J. NUCLEAR MED., vol. 39, no. 5suppl., May 1998 (1998-05-01), pages 99 - 100, XP000857227 *
DEWEY ET AL.: "A novel strategy for the treatment of cocaine addiction", SYNAPSE, vol. 30, no. 2, October 1998 (1998-10-01), pages 119 - 129, XP000856612 *
DEWEY ET AL.: "A pharmacologic strategy for the treatment of nicotine addiction", SYNAPSE, vol. 31, no. 1, January 1999 (1999-01-01), pages 76 - 86, XP000856613 *
DEWEY ET AL.: "GABAergic attenuation of cocaine-induced dopamine release and locomotor activity", SYNAPSE, vol. 25, no. 4, 1997, pages 393 - 398, XP000856597 *
KUSHNER ET AL.: "Comparison of the effects of vigabatrin on cocaine self-administration and food reinforcement", SOC. NEUROSCI. ABSTR., vol. 23, no. 1-2, 1997, pages 1942, XP002127040 *
KUSHNER ET AL.: "Gamma-vinyl GABA attenuats cocaine-induced lowering of brain stimulation reward thresholds", PSYCHOPHARMACOLOGIA, vol. 133, no. 4, 11 November 1997 (1997-11-11), pages 383 - 388, XP000856604 *
KUSHNER ET AL.: "The irreversible Gamma-aminobutyric acid (GABA) transaminase inhibitor Gamma-vinyl-GABA blocks cocaine self-administration in rats", J. PHARMACOL. EXP. THER., vol. 290, no. 2, 19 July 1999 (1999-07-19), pages 797 - 802, XP002127042 *
MORGAN ET AL.: "Effects of pharmacologic increases in brain GABA levels on cocaine-induced changes in extracellular dopamine", SYNAPSE, vol. 28, no. 1, January 1998 (1998-01-01), pages 60 - 65, XP002127041 *
MORGAN ET AL.: "Vigabatrin attenuates cocaine-induced changes in brain dopamine concentrations", J. NUCLEAR MED., vol. 38, no. 5suppl., 1997, pages 11p, XP000857224 *
ROBERTS ET AL.: "Baclofen attenuates the reinforcing effects of cocaine in rats", NEUROPSYCHOPHARMACOLOGY, vol. 15, no. 4, 1996, pages 417 - 423, XP002127043 *
TAKADA ET AL.: "Drug dependence study on Vigabatrin in Rhesus monkeys and rats", ARZNEIMITTEL FORSCHUNG, vol. 47, no. 10, October 1997 (1997-10-01), pages 1087 - 1092, XP000857211 *
TSUJI ET AL.: "Activation of ventral tegmental GABA-B receptors inhibits morphine-induced place preference in rats", EUR. J. PHARMACOL., vol. 313, no. 3, 17 October 1996 (1996-10-17), pages 169 - 173, XP002127044 *

Also Published As

Publication number Publication date
PL347912A1 (en) 2002-04-22
NO20010539L (en) 2001-04-02
PT1102583E (en) 2006-10-31
MXPA01001268A (en) 2003-07-14
HUP0103377A3 (en) 2003-11-28
ATE328588T1 (en) 2006-06-15
CN1172663C (en) 2004-10-27
JP2002522383A (en) 2002-07-23
HRP20010085A2 (en) 2002-02-28
CA2339192C (en) 2009-12-22
NZ509682A (en) 2004-01-30
WO2000007583A2 (en) 2000-02-17
NO20010539D0 (en) 2001-01-31
TWI243674B (en) 2005-11-21
US20020037925A1 (en) 2002-03-28
US6541520B1 (en) 2003-04-01
AU772715B2 (en) 2004-05-06
IL141067A0 (en) 2002-02-10
CZ2001394A3 (en) 2001-08-15
ID28916A (en) 2001-07-12
CY1105214T1 (en) 2010-03-03
BR9912760A (en) 2001-10-09
CN1326342A (en) 2001-12-12
EP1102583B1 (en) 2006-06-07
US6593367B1 (en) 2003-07-15
CA2339192A1 (en) 2000-02-17
US6906099B2 (en) 2005-06-14
DE69931789T2 (en) 2007-05-24
ES2267287T3 (en) 2007-03-01
DE69931789D1 (en) 2006-07-20
PL198789B1 (en) 2008-07-31
US6323239B1 (en) 2001-11-27
DK1102583T3 (en) 2006-10-09
EP1102583A2 (en) 2001-05-30
HUP0103377A2 (en) 2002-01-28
AU5545299A (en) 2000-02-28

Similar Documents

Publication Publication Date Title
WO2000007583A3 (en) Treatment of addiction and addiction-related behavior
Glick et al. Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum
CA2278507A1 (en) Method for treatment of cns-involved lysosomal storage diseases
EP2612553A1 (en) Compositions and Methods for Prophylaxis and Treatment of Addictions
JP2002522383A5 (en)
WO2000016762A3 (en) Method for reducing nicotine dependency
US20070167438A1 (en) Treatment of substance abuse
CA2193799A1 (en) Dopamine d1 agonists for the treatment of dementia
US6890951B2 (en) Treatment of addiction and addiction-related behavior
WO2000071108A3 (en) Methods for treatment of asthma using s-oxybutynin
HK1024631A1 (en) Use of (+) mefloquine for the treatment of malaria
WO2000010554A3 (en) Methods and compositions employing optically pure s(+) vigabatrin
US4355044A (en) D-Phenylalanine treatment
US6713497B1 (en) Use of vitamin B6 to mitigate visual field defects associated with the use of GABAergic drugs in mammals
WO2002091990A3 (en) Prevention of addiction in pain management
US4431670A (en) D-Phenylalanine treatment
McCarty Nutritional support of central catecholaminergic tone may aid smoking withdrawal
YU9101A (en) Treating of addiction and addiction-related behavior
EP0013110B1 (en) Analgesic composition
AU2001292499A1 (en) 7-chloro-4-hydroxy-2-(2-pyridylethyl)-1,2,5,10- tetrahydropyridazino(4,5-b)quinoline-1,10-dione and the use thereof for the treatment of pain
AU2005237538B2 (en) Methods of diminishing co-abuse potential
CA2345521A1 (en) Use of 3-(1h-imidazol-4-ylmethyl)-indan-5-ol in the manufacture of a medicament for intraspinal, intrathecal or epidural administration
Ng et al. On understanding and treating narcotic dependence: a neuropsychopharmacological perspective
Brown Complications of regional blocks: what do we really know?
WO1999063935A3 (en) Rapid opioid detoxification therapy and anti-readdiction therapy

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-91/01

Country of ref document: YU

Ref document number: 99811762.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 141067

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PV2001-394

Country of ref document: CZ

Ref document number: 55452/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2339192

Country of ref document: CA

Ref document number: 2339192

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 509682

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/001268

Country of ref document: MX

Ref document number: P20010085A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: 1020017001525

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1999941982

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999941982

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2001-394

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020017001525

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 55452/99

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1999941982

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1020017001525

Country of ref document: KR